Data may be intentionally delayed pursuant to supplier requirements. (wichtig)Pre-market Movers In Healthcare Sector: SNOA, AMYT, IBIO, CVAC, PRPO… Das sind die überraschenden Gründe dafür!DONNERSTAG WIRD WICHTIG: CureVac Aktie morgen an wichtigem Wendepunkt. Orchard Therapeutics plc (NASDAQ:ORTX) trade information. 5 Wall Street analysts have issued ratings and price targets for Orchard Therapeutics in the last 12 months. Orchard Therapeutics PLC is a United Kingdom-based commercial-stage, a fully-integrated biopharmaceutical company. Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. Why Orchard Therapeutics Stock Is Soaring Today. Das ist der unerwartete Grund! The company focuses on its autologous ex vivo gene therapy approach on three therapeutic... Data are provided 'as is' for informational purposes only and are not intended for trading purposes. Orchard Rx is … MotleyFool 15d: Orchard Therapeutics Announces Clinical Data Presentations at the 46th Annual Meeting of … In the face of being in the red today for losing -1.23%, in the last five days ORTX remained trading in the green while hitting it’s week-highest on Monday, Aug 03 when the stock touched $5.20-7 price level, adding 7.12% to its value on the day. View the latest Orchard Therapeutics PLC ADR (ORTX) stock price, news, historical charts, analyst ratings and financial information from WSJ. Orchard Therapeutics' stock was down by more than 60% year to date before today, and perhaps investors who finally felt as though the price was right bid up the company's shares. Their average twelve-month price target is $24.60, predicting that the stock has a possible upside of 344.04%. FactSet (a) does not make any express or implied warranties of any kind regarding the data, including, without limitation, any warranty of merchantability or fitness for a particular purpose or use; and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom. ORCHARD THERAPEUTICS PLC ADR-Investoren interessieren sich auch für diese NewsSie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von Breaking Covid-19 News: Auf die Plätze - fertig - Kursexplosion! Orchard Therapeutics is a global gene therapy leader dedicated to transforming the lives of people affected by rare diseases through the development of innovative, potentially curative gene … The company is engaged in transforming the lives of patients with serious and life-threatening rare diseases through autologous ex vivo gene therapies. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy." Share your opinion and gain insight from other stock traders and investors. Why Orchard Therapeutics Stock Is Soaring Today: 23: The Motley Fool: 24.08. It operates in three geographic regions: the United Kingdom, European Union, and the United States. The Investor Relations website contains information about Orchard Therapeutics's business for stockholders, potential investors, and financial analysts.
?ACHTUNG: Paion Aktionäre sind heute in Zugzwang und müssen reagieren.
The high price target for ORTX is $31.00 and the low price target for ORTX is $17.00. Find the latest Orchard Therapeutics plc (ORTX) stock discussion in Yahoo Finance's forum.